DE60327315D1 - Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind - Google Patents

Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind

Info

Publication number
DE60327315D1
DE60327315D1 DE60327315T DE60327315T DE60327315D1 DE 60327315 D1 DE60327315 D1 DE 60327315D1 DE 60327315 T DE60327315 T DE 60327315T DE 60327315 T DE60327315 T DE 60327315T DE 60327315 D1 DE60327315 D1 DE 60327315D1
Authority
DE
Germany
Prior art keywords
opiat
selective
compounds
effective
receptor modulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60327315T
Other languages
German (de)
English (en)
Inventor
Frank Weber
Jutta Jacob
Andrew Barber
Rudolf Gottschlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tioga Pharmaceuticals Inc
Original Assignee
Tioga Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tioga Pharmaceuticals Inc filed Critical Tioga Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60327315D1 publication Critical patent/DE60327315D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60327315T 2002-05-17 2003-04-28 Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind Expired - Lifetime DE60327315D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011047 2002-05-17
PCT/EP2003/004428 WO2003097051A2 (en) 2002-05-17 2003-04-28 Use of compounds that are effective as selective opiate receptor modulators

Publications (1)

Publication Number Publication Date
DE60327315D1 true DE60327315D1 (de) 2009-06-04

Family

ID=29433078

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60327315T Expired - Lifetime DE60327315D1 (de) 2002-05-17 2003-04-28 Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind

Country Status (20)

Country Link
US (1) US20050176746A1 (https=)
EP (2) EP1505974B1 (https=)
JP (1) JP2005531557A (https=)
KR (1) KR101108014B1 (https=)
CN (2) CN101310723A (https=)
AR (1) AR040028A1 (https=)
AT (1) ATE429226T1 (https=)
AU (1) AU2003242527B2 (https=)
BR (1) BR0309969A (https=)
CA (1) CA2486000A1 (https=)
DE (1) DE60327315D1 (https=)
DK (1) DK1505974T3 (https=)
ES (1) ES2325782T3 (https=)
MX (1) MXPA04011333A (https=)
PE (1) PE20040455A1 (https=)
PL (1) PL371596A1 (https=)
RU (1) RU2336871C2 (https=)
TW (1) TWI314053B (https=)
WO (1) WO2003097051A2 (https=)
ZA (1) ZA200410160B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10259245A1 (de) * 2002-12-17 2004-07-01 Merck Patent Gmbh Derivate des Asimadolins mit kovalent gebundenen Säuren
SG168407A1 (en) 2003-01-28 2011-02-28 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1870096A3 (en) * 2003-04-29 2011-04-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
CN101677997B (zh) * 2007-03-30 2012-05-09 泰奥加制药公司 用于治疗腹泻型和交替型肠易激综合征的κ-阿片剂激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2994066A1 (en) 2008-12-03 2010-06-10 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
SI2384318T1 (en) 2008-12-31 2018-03-30 Ardelyx, Inc. MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT
RU2413512C1 (ru) * 2009-07-29 2011-03-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" Средство, обладающее каппа-опиоидной агонистической активностью
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
WO2012012410A2 (en) * 2010-07-19 2012-01-26 Dr. Reddy's Laboratories Ltd. Kappa opioid receptor agonists
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
ES2664873T3 (es) 2011-03-01 2018-04-23 Synergy Pharmaceuticals Inc. Proceso de preparación de agonistas de guanilato ciclasa C
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
MX366293B (es) 2012-08-21 2019-07-04 Ardelyx Inc Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
LT2983667T (lt) 2013-04-12 2019-07-10 Ardelyx, Inc. Nhe3 rišantys junginiai ir fosfato pernešimo slopinimo būdai
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
EA023231B1 (ru) * 2013-07-18 2016-05-31 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН) Применение агониста каппа опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения синдрома отмены никотина
US20160250277A1 (en) * 2013-10-28 2016-09-01 Cara Therapeutics, Inc. Peripheral kappa opioid receptor agonists for preventing, inhibiting or treating nausea and vomiting
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
CA3049678A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
DE3935371A1 (de) 1988-12-23 1990-07-05 Merck Patent Gmbh Stickstoffhaltige ringverbindungen
DE4034785A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh 1-(2-arylethyl)-pyrrolidine
US5389686A (en) * 1989-02-20 1995-02-14 Jouveinal Sa Analgesic properties of fedotozine
DE4215213A1 (de) 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
DE4215231C1 (en) 1992-05-09 1993-05-13 Dornier Luftfahrt Gmbh, 8031 Wessling, De Arrangement for mfg. fibre reinforced thermoplastic components - including unit for accommodating component, pressurising unit for assembled component and heating unit
DE19523502A1 (de) * 1995-06-28 1997-01-02 Merck Patent Gmbh Kappa-Opiatagonisten für entzündliche Darmerkrankungen
DE19531464A1 (de) * 1995-08-26 1997-02-27 Merck Patent Gmbh N-Methyl-N-[(1S-)-1-phenyl-2-((3S)-3-hydroxypyrrolidin 1-yl-)-ethyl]-2,2-diphenyl-acetamid
IL135258A0 (en) * 1997-09-26 2001-05-20 Noven Pharma Bioadhesive compositions and methods for topical administration of active agents
US20010051181A1 (en) * 1997-12-22 2001-12-13 Van Osdol William W. Novel formulations for the transdermal administration of asimadoline
JPH11343244A (ja) * 1998-03-30 1999-12-14 Taisho Pharmaceut Co Ltd 経口用組成物
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
WO2000004050A2 (en) * 1998-07-14 2000-01-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
WO2001097753A2 (en) * 2000-06-19 2001-12-27 Eisai Co. Ltd. Novel methods using pyridine derivatives
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
DE10030893A1 (de) * 2000-06-23 2002-01-03 Henkel Kgaa Paraaminophenol-Derivate und deren Verwendung
US6262062B1 (en) * 2000-08-15 2001-07-17 Cpd, Llc Method of treating the syndrome of coronary heart disease risk factors in humans
US6569449B1 (en) * 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US6780891B2 (en) * 2001-11-30 2004-08-24 Sepracor Inc. Tramadol analogs and uses thereof

Also Published As

Publication number Publication date
DK1505974T3 (da) 2009-08-17
KR20050010807A (ko) 2005-01-28
TWI314053B (en) 2009-09-01
AR040028A1 (es) 2005-03-09
RU2336871C2 (ru) 2008-10-27
ES2325782T3 (es) 2009-09-17
ZA200410160B (en) 2005-12-28
US20050176746A1 (en) 2005-08-11
AU2003242527A1 (en) 2003-12-02
EP1505974A2 (en) 2005-02-16
HK1079451A1 (zh) 2006-04-07
CN100411618C (zh) 2008-08-20
KR101108014B1 (ko) 2012-01-25
BR0309969A (pt) 2005-04-26
TW200307541A (en) 2003-12-16
WO2003097051A3 (en) 2004-12-09
ATE429226T1 (de) 2009-05-15
PL371596A1 (en) 2005-06-27
MXPA04011333A (es) 2005-02-14
AU2003242527B2 (en) 2008-10-23
RU2004137091A (ru) 2005-09-10
WO2003097051A2 (en) 2003-11-27
CA2486000A1 (en) 2003-11-27
CN1655784A (zh) 2005-08-17
PE20040455A1 (es) 2004-08-07
CN101310723A (zh) 2008-11-26
EP2074997A1 (en) 2009-07-01
JP2005531557A (ja) 2005-10-20
EP1505974B1 (en) 2009-04-22

Similar Documents

Publication Publication Date Title
DE60327315D1 (de) Verwendung von verbindungen, die als selektive opiat-rezeptor-modulatoren wirksam sind
DE60209736D1 (de) Piperidinverbindungen, die sich als modulatoren der chemokinrezeptoraktivität eignen
LTPA2017005I1 (lt) Nauji junginiai, kaip opioido receptoriaus moduliatoriai
ATE416168T1 (de) Modulatoren des vanilloidrezeptors
DK1592658T3 (da) Syntese af selektive, androgene receptormodulatorer i stor målestok
ATE525377T1 (de) Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
DE602004019118D1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
DE602004015451D1 (de) Sulphonamidverbindungen, die die chemokinrezeptoraktivität (ccr4) modulieren
ATE549329T1 (de) Chinazoline verbindungen
DE602004010791D1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
ATE344254T1 (de) 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren
ATE403650T1 (de) 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren
ATE453629T1 (de) Chinazolin-verbindungen als ionenkanal modulatoren
DE60322453D1 (de) System zum Bereitstellen von Diensten
NO20043555D0 (no) Selvstyrende bronn intervensjonssytem
ATE544762T1 (de) Calcium rezeptor modulatoren
DK1637527T3 (da) Cannabinoid receptor modulator.
ATE323081T1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
MA27306A1 (fr) Ligands des recepteurs de la melanocortine.
DE60325146D1 (de) Fahrerhausrahmen
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
DE10326239B4 (de) Schnellwechselsystem
DE602004017892D1 (de) Bicyclische amid-, carbamat- oder harnstoffderivate als modulatoren des vanilloidrezeptors
NO20055752D0 (no) N-ureidoalkyl-piperidiner som modulerer forbindelser av kjemokinreseptor-aktivitet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition